1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment

$4.8bn MBO Japan's Largest

 
• By Lisa Takagi

The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.

By privatizing the firm, Taisho aims to implement several measures that would upset the firm's finance for an instant.
Taisho aims to progress business, R&D through take-private move • Source: Shutterstock

Taisho Pharmaceutical Holdings, which owns one of Japan’s largest pharmaceutical firms, over-the-counter focused Taisho Pharmaceutical Co., Ltd., initiated in late November what is set to be the largest management buyout (MBO) in the country’s corporate history, worth close to $5bn.

The founding Uehara family, which holds the single-largest combined stake in the company, has said it is seeking the take-private move to smooth the implementation of "dynamic measures" for the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

More from Focus On Asia